Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment
Maria Chalia, Emilie Seager, Anupama Rao, Simon HannamGreat Ormond Street Hospital for Children.United Kingdom Acta PaediatricaActa Paediatr 2024; DOI: 10.1111/apa.17142 AbstractAim: Five to thirty percent of neonates with trisomy 21 develop transient abnormal myelopoiesis (TAM) with a high mortality rate. The aim of the study was to identify contributing factors that determine mortality and need for chemotherapy
Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment Read More »
